Pharmaceutical company Torrent Pharmaceuticals Ltd delivered exceptional market performance alongside its strong financial results, with shares hitting a new all-time high of ₹4,322.80 on Friday, February 13, representing a 6% surge from the previous close of ₹4,074.05. According to Samco Trading reports, this record high came despite a muted broader market session where the Sensex was up just 0.20% at 82,773. The stock's outperformance reflects strong investor confidence in the company's operational efficiency and earnings growth trajectory. The December quarter often carries weight as it reflects festive demand trends, seasonal adjustments, and business momentum heading into the final quarter of the financial year.
Pharmaceutical company Torrent Pharmaceuticals Ltd reported robust financial results for Q3 FY26, with consolidated net profit surging 26% year-on-year to ₹635 crore compared to ₹503 crore in the same period last year. According to reports from Business Standard, the company's revenue grew 17.6% to ₹3,303 crore versus ₹2,809 crore in Q3 FY25. On a sequential basis, net profit grew by 7.4% while revenue from operations remained flat. The growth can be attributed to robust performance across multiple markets and segments. Samco Trading analysis reveals that operational EBITDA came in at ₹1,088 crore, up 19% YoY, with EBITDA margin standing at 33%, demonstrating strong operational efficiency and profitability management.
The company's India revenue reached ₹1,798 crore, up 14% year-on-year, outperforming the Indian Pharmaceutical Market (IPM) which grew 10% during the quarter. As reported by Business Standard, Torrent Pharma outperformed the market in chronic and sub-chronic therapies, led by the cardiac, gastro, and diabetes (OAD) segments. For 9M FY26, India revenues stood at ₹5,430 crore, up 12% from the same period last year. The performance was driven by higher volumes in chronic and sub-chronic therapies, with the company outpacing the Indian pharmaceutical market growth.
The Brazil business delivered strong performance with revenues reaching ₹371 crore, up 27% year-on-year. According to IQVIA data reported by Business Standard, Torrent grew 13% versus market growth of 7%, driven by strong performance of key brands and recent launches. The company currently has 60 products under review with Brazil's regulator, Anvisa. The US business posted revenues of ₹321 crore, up 19% from the prior year, with constant currency revenues at $36 million, up 12%. For 9M FY26, US revenues grew 21% to ₹967 crore, while constant currency revenues rose 16% to $111 million, supported by recent product launches.
Torrent Pharma announced an interim dividend of ₹29 per equity share of ₹5, fully paid up, representing 580% of the face value. As reported by CNBC TV18, the dividend is expected to be paid or dispatched on or around 6th March 2026. Shares of Torrent Pharmaceuticals Ltd ended at ₹4,074.05, down by ₹7.55, or 0.18% on the BSE following the results announcement after market hours. Dividend announcements often add sentiment support, especially when accompanied by strong quarterly numbers, and the Q3 Result Impact was not limited to profits alone - the dividend decision reinforced confidence in the company's financial stability.
